TY - JOUR T1 - Prospective Evaluation of PSMA-Targeted <sup>18</sup>F-DCFPyL PET/CT in Men with Biochemical Failure After Radical Prostatectomy for Prostate Cancer JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 58 LP - 61 DO - 10.2967/jnumed.119.226514 VL - 61 IS - 1 AU - Steven P. Rowe AU - Scott P. Campbell AU - Margarita Mana-Ay AU - Zsolt Szabo AU - Mohamad E. Allaf AU - Kenneth J. Pienta AU - Martin G. Pomper AU - Ashley E. Ross AU - Michael A. Gorin Y1 - 2020/01/01 UR - http://jnm.snmjournals.org/content/61/1/58.abstract N2 - Our purpose is to provide the results of a prospective study evaluating prostate-specific membrane antigen–targeted 18F-DCFPyL (2-(3-{1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid) PET/CT in patients with biochemical failure after radical prostatectomy for prostate cancer (PCa). Methods: Thirty-one patients with postprostatectomy serum prostate-specific antigen (PSA) levels of at least 0.2 ng/mL and negative conventional imaging results were enrolled in this study and imaged with 18F-DCFPyL PET/CT. A consensus central review identified foci of radiotracer uptake consistent with sites of PCa. Descriptive statistics were used. Results: Twenty-one patients (67.7%) had at least 1 finding on 18F-DCFPyL PET/CT consistent with a site of PCa. Imaging was positive in 59.1% of patients with a PSA level of less than 1.0 ng/mL and in 88.9% of patients with a PSA level of more than 1.0 ng/mL. The median SUVmax across all lesions was 11.6 (range, 1.5–57.6). Conclusion: In this prospective study using the prostate-specific membrane antigen–targeted PET agent 18F-DCFPyL, most patients with biochemical failure after radical prostatectomy had foci of suggestive uptake, even at low serum PSA levels. ER -